Blue Coast Cardiology — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$176,565	11
2024	Research	$185,341	2
2023	Research	$188,031	4
2022	Research	$179,278	1
2019	Research	$37,475	4

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $720,156 9 payments
Amgen Inc. $31,363 3 payments
AstraZeneca Pharmaceuticals LP $7,823 2 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
Boehringer Ingelheim International GmbH $672 7 payments

Studies the money was for Research payments · program years 2019–2025

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $634,990 5 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $85,165 4 payments
FOURIER OLE (Ph 4) $29,652 2 payments
Forxiga HF-D1699C00001 HF rEF Outcome study $7,823 2 payments
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $7,349 8 payments
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $1,711 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.